These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37146834)

  • 21. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
    Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
    Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
    Samanta AK; Huang HJ; Le XF; Mao W; Lu KH; Bast RC; Liao WS
    Cancer; 2009 Sep; 115(17):3897-908. PubMed ID: 19517469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
    Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
    Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
    Ganta S; Amiji M
    Mol Pharm; 2009; 6(3):928-39. PubMed ID: 19278222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
    Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
    Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional co-activators.
    Kim RH; Flanders KC; Birkey Reffey S; Anderson LA; Duckett CS; Perkins ND; Roberts AB
    J Biol Chem; 2001 Dec; 276(49):46297-304. PubMed ID: 11567019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
    Wei S; Qi L; Wang L
    Anticancer Drugs; 2021 Jun; 32(5):496-507. PubMed ID: 33735118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
    Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells.
    Collett GP; Campbell FC
    Carcinogenesis; 2006 Jun; 27(6):1285-91. PubMed ID: 16497702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells.
    Li X; He Y; Wei L; Zhang J; Li X; Cui W; Zhang S
    J Pharm Pharmacol; 2021 Mar; 73(4):545-552. PubMed ID: 33793827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.